Africa stands out in the world for its relatively mild effect from COVID-19. Theories as to why this is the case are multiple running the gamut from underreporting and lack of testing to youthful population and genetic predisposition and even the wide use of ivermectin in numerous countries.

Thus far scientists haven’t been able to explain the reason for the continent’s overall low number of COVID-19 cases. Ivermectin is used by dozens of countries in the African continent as an intervention for onchocerciasis. With 67 studies now formally investigating ivermectin as a COVID-19 treatment the prospect of investigating the correlation of low African COVID-19 numbers prompted Japanese researchers to look into this most intriguing of explanations.

Hisaya Tanioka, MD, PhD and radiologist and Sayaka Tanioka, both with the Tanioka Clinic in the Bunkyo-Ku district of Tokyo along with Kimitaka Kaga with the National Institute of Sensory Organs, part of the National Hospital Organization, Tokyo Medical Center designed a retrospective statistical analysis study to investigate the impact of ivermectin against COVID-19 with a specific focus on comparing 31 African nations

Source –